FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149654934> ?p ?o ?g. }

• W2149654934 endingPage "391" @default.
• W2149654934 startingPage "385" @default.
• W2149654934 abstract "Three agents have received Food and Drug Administration (FDA) approval for treatment of chronic lymphocytic leukemia (CLL) within the past year. Ibrutinib and idelalisib block B-cell receptor signaling through inhibition of Bruton tyrosine kinase and phosphatidylinositol 3-kinase δ molecules respectively, interfering with several pathways required for leukemia cell survival. Idelalisib has shown efficacy in the relapsed setting and is currently approved by the FDA for use in combination with rituximab. Ibrutinib has been studied in patients with relapsed CLL and as frontline therapy. In the relapsed setting, these agents produce durable remissions, and might be preferable to re-treatment with chemoimmunotherapy for many patients. Ibrutinib is also effective treatment for patients with deletion 17p and is approved by the FDA as frontline therapy in this patient group, although it does not appear to completely abrogate this adverse prognostic factor. These agents have a unique side effect profile and longer follow-up is required to further understand tolerability and rare adverse effects. Obinutuzumab is a type-2 monoclonal anti-CD20 antibody which results in direct and antibody-dependent cell-mediated cytotoxicity of leukemia cells. It is approved by the FDA for use in combination with chlorambucil, and has shown efficacy in the frontline setting in patients unfit for more intensive chemoimmunotherapy. It produces increased response rates and minimal residual disease negativity compared with chlorambucil/rituximab and is associated with an advantage in progression-free survival but not yet overall survival. These agents underscore our advancement in the understanding of the biology of CLL and will improve outcomes for many patients with CLL." @default.
• W2149654934 created "2016-06-24" @default.
• W2149654934 creator A5006104041 @default.
• W2149654934 creator A5013684062 @default.
• W2149654934 creator A5027575595 @default.
• W2149654934 creator A5058755419 @default.
• W2149654934 creator A5089428686 @default.
• W2149654934 date "2015-07-01" @default.
• W2149654934 modified "2023-10-12" @default.
• W2149654934 title "Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice" @default.
• W2149654934 cites W152786914 @default.
• W2149654934 cites W1967796318 @default.
• W2149654934 cites W1973919081 @default.
• W2149654934 cites W1979834961 @default.
• W2149654934 cites W1988367968 @default.
• W2149654934 cites W1993192840 @default.
• W2149654934 cites W1993355130 @default.
• W2149654934 cites W1999532069 @default.
• W2149654934 cites W2001850157 @default.
• W2149654934 cites W2003089766 @default.
• W2149654934 cites W2013909810 @default.
• W2149654934 cites W2025707347 @default.
• W2149654934 cites W2027971058 @default.
• W2149654934 cites W2038053631 @default.
• W2149654934 cites W2040040334 @default.
• W2149654934 cites W2055886080 @default.
• W2149654934 cites W2066564017 @default.
• W2149654934 cites W2067064694 @default.
• W2149654934 cites W2071549499 @default.
• W2149654934 cites W2073550690 @default.
• W2149654934 cites W2074584895 @default.
• W2149654934 cites W2075875145 @default.
• W2149654934 cites W2077173862 @default.
• W2149654934 cites W2078083587 @default.
• W2149654934 cites W2083435401 @default.
• W2149654934 cites W2086296392 @default.
• W2149654934 cites W2091057822 @default.
• W2149654934 cites W2091664866 @default.
• W2149654934 cites W2095447519 @default.
• W2149654934 cites W2098289842 @default.
• W2149654934 cites W2099848513 @default.
• W2149654934 cites W2100707039 @default.
• W2149654934 cites W2108206643 @default.
• W2149654934 cites W2117648265 @default.
• W2149654934 cites W2120319857 @default.
• W2149654934 cites W2123666692 @default.
• W2149654934 cites W2124575836 @default.
• W2149654934 cites W2136846143 @default.
• W2149654934 cites W2140395974 @default.
• W2149654934 cites W2140606816 @default.
• W2149654934 cites W2142099365 @default.
• W2149654934 cites W2145842706 @default.
• W2149654934 cites W2149515595 @default.
• W2149654934 cites W2151177887 @default.
• W2149654934 cites W2163577434 @default.
• W2149654934 cites W2163690533 @default.
• W2149654934 cites W2166470267 @default.
• W2149654934 cites W2171771895 @default.
• W2149654934 cites W2515639723 @default.
• W2149654934 cites W2604070126 @default.
• W2149654934 cites W981207258 @default.
• W2149654934 doi "https://doi.org/10.1016/j.clml.2015.02.019" @default.
• W2149654934 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4905707" @default.
• W2149654934 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25817936" @default.
• W2149654934 hasPublicationYear "2015" @default.
• W2149654934 type Work @default.
• W2149654934 sameAs 2149654934 @default.
• W2149654934 citedByCount "27" @default.
• W2149654934 countsByYear W21496549342015 @default.
• W2149654934 countsByYear W21496549342016 @default.
• W2149654934 countsByYear W21496549342017 @default.
• W2149654934 countsByYear W21496549342018 @default.
• W2149654934 countsByYear W21496549342019 @default.
• W2149654934 countsByYear W21496549342020 @default.
• W2149654934 countsByYear W21496549342022 @default.
• W2149654934 countsByYear W21496549342023 @default.
• W2149654934 crossrefType "journal-article" @default.
• W2149654934 hasAuthorship W2149654934A5006104041 @default.
• W2149654934 hasAuthorship W2149654934A5013684062 @default.
• W2149654934 hasAuthorship W2149654934A5027575595 @default.
• W2149654934 hasAuthorship W2149654934A5058755419 @default.
• W2149654934 hasAuthorship W2149654934A5089428686 @default.
• W2149654934 hasBestOaLocation W21496549342 @default.
• W2149654934 hasConcept C126322002 @default.
• W2149654934 hasConcept C143998085 @default.
• W2149654934 hasConcept C2777607594 @default.
• W2149654934 hasConcept C2777938653 @default.
• W2149654934 hasConcept C2778461978 @default.
• W2149654934 hasConcept C2779260929 @default.
• W2149654934 hasConcept C2779878957 @default.
• W2149654934 hasConcept C71924100 @default.
• W2149654934 hasConceptScore W2149654934C126322002 @default.
• W2149654934 hasConceptScore W2149654934C143998085 @default.
• W2149654934 hasConceptScore W2149654934C2777607594 @default.
• W2149654934 hasConceptScore W2149654934C2777938653 @default.
• W2149654934 hasConceptScore W2149654934C2778461978 @default.
• W2149654934 hasConceptScore W2149654934C2779260929 @default.
• W2149654934 hasConceptScore W2149654934C2779878957 @default.

• next